Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence

Volume: 15, Issue: 6, Pages: 395 - 404
Published: Nov 1, 2019
Abstract
Direct oral anticoagulants are associated with lower rates of bleeding than vitamin K antagonists, but life-threatening bleeding still occurs. Andexanet alfa is a catalytically inactive recombinant modified human factor Xa molecule that reverses the anticoagulant effect of direct and indirect acting factor Xa inhibitors. In the ANNEXA-4 study, treatment with andexanet was associated with a 92% reduction in median anti-Xa activity levels and...
Paper Details
Title
Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence
Published Date
Nov 1, 2019
Volume
15
Issue
6
Pages
395 - 404
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.